27.6 C
New York
Wednesday, June 3, 2026

Tag: patients

newssourceFORcompanyinformationcontent1marketreleases

AMERICAN SKIN ASSOCIATION ANNUAL GALA RECOGNIZES SUN PHARMA WITH CORPORATE LEADERSHIP AWARD

Specialty and Generic Medicines Leader Honored for Dedication to the Dermatology FieldNEW YORK, June 3, 2026 /PRNewswire/ -- On Tuesday evening at The Plaza...

Mercedes-Benz of Westwood Celebrates Grand Opening of Newly Renovated Luxury Dealership

Multi-phase renovation introduces expanded showroom, enhanced service drive, AMG Performance Center displays, EV infrastructure, and updated customer amenitiesWESTWOOD, Mass., June 3, 2026 /PRNewswire/ --...

In HelloNation, Holistic Health Expert Cynde Schneider Discusses How Integrative Medicine Differs From Traditional Medical Care

LAMESA, Texas, June 3, 2026 /PRNewswire/ -- The article explores how personalized care and lifestyle-focused evaluations support long-term overall wellness. ...

Disclosure of transparency notification from FMR LLC

Regulated information
Nazareth (Belgium)/Rotterdam (The Netherlands), 3 June 2026 – 6 PM CET

Medical Grade Physiotherapy & Wellness Now Accepting New Clients in Burlington, Ontario — Redefining One-on-One Rehabilitation & Wellness Care

Burlington, Ontario physiotherapy clinic offering injury rehab, chiropractic care, registered massage therapy, back pain relief, neck pain treatment.

ProBio and GCP ClinPlus Partner to Accelerate Clinical Trials in China

ProBio and GCP ClinPlus today announced a strategic collaboration designed to accelerate Investigator-Initiated Trials (IITs) in China and provide integrated, end-to-end clinical and development...

Coloplast’s Next Generation Inflatable Penile Prosthesis Approved by the FDA – can help millions of men

The global leader within intimate healthcare today announced FDA approval of Titan Prime, an inflatable penile prosthesis (IPP) that represents the company’s next-generation device and will be available in the U.S. in late 2026. 

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial...

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2

Levicept to Present Data Suggesting LEVI-04 May Modify Disease in Osteoarthritis at EULAR 2026

Further clinical efficacy and pharmacology data also to be presented 
Further clinical efficacy and pharmacology data also to be presented

MindMaze Therapeutics Publishes Invitation to the 2026 Annual General Meeting

GENEVA, June 3, 2026 /PRNewswire/ -- MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics,...

Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care

Novo Nordisk is launching Wegovy® pill in the UAE, the first country outside the US, to make the Wegovy® pill available to people living with obesity

JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)

Warsaw, Poland – June 03, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotech that engineers precision antibodies to correct derailed immune pathways that drive autoimmune diseases and cancer, today announces positive interim data from its ongoing Phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class anti-CD89 antagonist, in patients diagnosed with Linear IgA Disease (LAD), a rare autoantibody-mediated skin disease.

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and...

ASCO 2026 | Updated Data from an Oral Presentation of InnoCare’s Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released

InnoCare's novel BCL2i mesutoclax in MDS and AML was released at 2026 ASCO as an oral presentation, demonstrating outstanding efficacy and safety.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPatients

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers